First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial

Lung, Respiratory and Thoracic Cancer
Do you want to read an article? Please log in or register.